NCT03665038 - A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 7, 2018

Primary Completion Date

January 8, 2021

Study Completion Date

January 8, 2021

Conditions

Post Partum Depression

Interventions

DRUG

Brexanolone

Administered as IV infusion.

Trial Locations (17)

27599

Sage Investigational Site, Chapel Hill

30030

Sage Investigational Site, Decatur

30331

Sage Investigational Site, Atlanta

32502

Sage Investigational Site, Pensacola

32807

Sage Investigational Site, Orlando

33029

Sage Investigational Site, Miramar

33060

Sage Investigational Site, Pompano Beach

33782

Sage Investigational Site, Pinellas Park

39216

Sage Investigational Site, Jackson

39232

Sage Investigational Site, Flowood

41017

Sage Investigational Site, Edgewood

42303

Sage Investigational Site, Owensboro

44130

Sage Investigational Site, Middleburg Heights

72758

Sage Investigational Site, North Little Rock

77058

Sage Investigational Site, Houston

77573

Sage Investigational Site, League City

85226

Sage Investigational Site, Tempe

All Listed Sponsors

lead

Supernus Pharmaceuticals, Inc.

INDUSTRY